Differential targeting of the cyclin-dependent kinase inhibitor, p21 CIP1/WAF1 , by chelators with anti-proliferative activity in a range of tumor cell-types
1 March 2018 in Biochimica et Biophysica Acta (BBA) - General Subjects
In this issue of the Journal, Guadamuz et al. ( 1) report on the relationship between social determinants of health (SDOH) and cancer clinical trial participation among Black and Latinx patients in the Flatiron Health database, which includes data on more than 250 000 patients from 2011 to 2023. Unsurprisingly, they reaffirm substantial disparities in clinical trial participation. Black and Latinx patients are 40%-50% less likely to participate in clinical trials than White patients, despite clear US laws, such as the 1993 National Institutes of Health Revitalization Act ( 2) and laws mandating insurance coverage for trials. This study, however, provides quantifiable estimates of the contribution of different mediators to these disparities, which is a notable step forward in the trial participation literature. As shown in previous studies ( 3), it does not appear that patients from minoritized populations decline offers of trial participation—rather, they are not provided with the opportunity to participate because of where they reside or health-care professional biases. Similar to their previous research ( 4), the authors link trial data to American Community Survey and US Census Bureau data and relate area-level SDOH factors to the outcome of interest. This database linkage enables the authors to explore the disparity thoroughly through mediation analysis. They demonstrate that area-level SDOH, particularly measures of structural racism and practical obstacles, account for the majority of inequity in trial participation. Neighborhood racial and ethnic composition, a proxy for segregation, was considered the most substantial mediator and explained one-third of the inequities between Black, Latinx, and White patients. The authors point to site factors such as clinician bias and institutional racism and to sponsor factors such as their preference for partnering with well-resourced cancer care facilities, which tend not to serve minority populations. At the patient level, the authors ( 1) show that area-level vehicle ownership was an important mediator, highlighting a tangible opportunity to improve equity by providing transportation assistance. Limited proficiency in English was an important mediator of Latinx-White inequity and provides further evidence of the importance of providing reliable interpreter access and translated materials.
Background: Culturally and ethnically diverse communities are underrepresented in cancer clinical trials, further contributing to existing health inequities. Research often overlooks how upstream social determinants of health (SDOH) might contribute to these inequities, instead focusing on individual-level barriers. Arabic is the third most spoken language in Australia and is the focus of this study. This study aims to explore how upstream SDOH influence clinical trial participation among Arabic-speaking cancer patients (ASCPs), as perceived by healthcare professionals (HCPs). Methods: A qualitative study comprising virtual focus groups with HCPs with experience recruiting ASCPs into clinical trials. Participants were recruited via professional networks and social media using snowball sampling. The Sociocultural Framework for Health Service Disparities was used to identify perceived barriers and enablers to cancer clinical trial participation relating to structural, healthcare provider, and environmental factors. Focus groups were analysed using the Best Fit approach by two independent coders. Results: Fourteen participants were recruited (ten medical specialists, two nurses, one clinical trial coordinator and one researcher). Structural and healthcare provider barriers centred on English-language proficiency. Structural barriers included limited consultation time, restrictive trial eligibility criteria, lack of translated study materials, and a lack of workforce diversity. Language discourse reduced HCPs’ confidence in patient understanding of trial information and consequently the informed consent procedure. By advocating for translated materials, booking longer consults, and engaging interpreters, HCPs became enablers to trial participation. Family support networks were identified as environmental enablers by facilitating trial-related conversations; however, they also acted as barriers by compromising patient autonomy in decision-making. Perceived scepticism and distress emerged as environmental barriers that shaped attitudes toward cancer diagnosis and trial participation. Conclusion: Findings highlight how upstream SDOH can create barriers to cancer clinical trial access, thereby reducing opportunities for participation among ASCPs in Australia. Although the barriers were described in terms of language, they may reflect a broader lack of cultural competency. Further research into strategies integrating enablers such as time, workforce diversity, interpreter engagement and translated resources is essential to inform inclusive healthcare systems and research design, with potential implications beyond the Arabic-speaking community. Trial registration: Ethical approval for this study was granted by the University of Technology Sydney Human Research Ethics Committee (ETH21-6506, 14/01/2022).